Evidence map›Paper›PMID 11774028›Full record

ArticleNeoplasia (New York, N.Y.)

Matrilysin [MMP-7] expression selects for cells with reduced sensitivity to apoptosis.

B Fingleton, T Vargo-Gogola, H C Crawford, L M Matrisian

Open access · goldAbstract read
In one paragraph

Article in Neoplasia (New York, N.Y.). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
59citing papers in PubMed, 1 pooled it
3.4field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

59 citing papers in PubMed, 1 synthesis or guideline pooled it, 156 citations in OpenAlex.

  1. Prognostic value of matrix metalloproteinase-7 expression in patients with non-small cell lung cancer.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014
    Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. sFasL-The Key to a Riddle: Immune Responses in Aging Lung and Disease.International journal of molecular sciences · 2021
    Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Matrix-metalloproteinases as targets for controlled delivery in cancer: An analysis of upregulation and expression.Journal of controlled release : official journal of the Controlled Release Society · 2017
    Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

B FingletonDepartment of Cancer Biology, Vanderbilt University School of Medicine, PRB 23rd and Pierce, Nashville, TN 37232-6840, USA. barbara.fingleton@mcmail.vanderbilt.edu
T Vargo-Gogola
H C Crawford
L M Matrisian
Vanderbilt University · US

Funding

Tumor Immunology and Microenvironment Research ProgramP30CA068485 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI MATTHEW J TYSKA · 1995 to 2026
$172.8M
THE ROLE OF MATRILYSIN IN TUMOR PROGRESSIONR01CA060867 · NCI · VANDERBILT UNIVERSITY · PI MATRISIAN, LYNN M · 1993 to 2006
$4.1M
NCI NIH HHS P30 CA068485NCI NIH HHS P30 CA68485NCI NIH HHS R01 CA060867NCI NIH HHS R01 CA60867
6 · The paper itself

Abstract

The matrix metalloproteinase matrilysin (MMP-7) has been demonstrated to contribute to tumor development. We have shown previously that members of the TNF family of apoptosis-inducing proteins are substrates for this enzyme, resulting in increased death pathway signaling. The goal of the current study was to reconcile the proapoptotic and tumor-promoting functions of matrilysin. In the human HBL100 and murine NMuMG cell lines that represent early stages of tumor progression and that express both Fas ligand and its receptor, exposure to matrilysin results in cell death that can be blocked by FasL neutralizing antibodies. Constitutive expression of matrilysin in these cell lines selects for cells with reduced sensitivity to Fas-mediated apoptosis as demonstrated both with a receptor-activating antibody and with in vitro activated splenocytes. Matrilysin-expressing cells are also significantly less sensitive to chemical inducers of apoptosis. We propose that the expression of matrilysin that has been reported at early stages in various tumor types can act to select cells with a significantly decreased chance of removal due to immune surveillance. As a result, these cells are more likely to acquire additional genetic modifications and develop further as tumors.

Indexed as

AnimalsAntibodies, MonoclonalApoptosisBreastClone CellsConcanavalin ACycloheximideDNA, ComplementaryEnzyme InductionEnzyme InhibitorsEpithelial CellsFas Ligand Proteinfas ReceptorFemaleHumansInterleukin-2Antibodies, MonoclonalConcanavalin ACycloheximideDNA, ComplementaryEnzyme InhibitorsFASLG protein, humanFaslg protein, ratFas Ligand ProteinFasl protein, mousefas ReceptorInterleukin-2Matrix Metalloproteinase 7Membrane GlycoproteinsMitomycinProtein Synthesis InhibitorsRecombinant Fusion ProteinsStaurosporine

Identifiers

PMID11774028
PMCPMC1506562
OpenAlexW2000334113

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.